Tafolecimab monotherapy reduced low-density lipoprotein cholesterol by more than 60% at week 12 in phase 3 CREDIT-5 results
In topline phase 3 CREDIT-5 results, tafolecimab monotherapy reduced low-density lipoprotein cholesterol by more than 60% at week 12 versus ...
Get the app